{"id":2396,"date":"2015-07-31T18:54:43","date_gmt":"2015-07-31T18:54:43","guid":{"rendered":"https:\/\/www.lymphoma.ca\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/"},"modified":"2015-07-31T18:54:43","modified_gmt":"2015-07-31T18:54:43","slug":"une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib","status":"publish","type":"post","link":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/","title":{"rendered":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib"},"content":{"rendered":"<p>Une recherche r\u00e9cente a montr\u00e9 que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B  (DLBCL) sont plus susceptibles de r\u00e9pondre \u00e0 l\u2019ibrutinib (Imbruvica) que des patients<br \/>\n<!--more--><\/p>\n<h2>Une recherche met en \u00e9vidence un espoir de m\u00e9decine de pr\u00e9cision pour le type le plus courant de lymphome.<\/h2>\n<p>Une recherche r\u00e9cente a montr\u00e9 que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B&nbsp; (DLBCL) sont plus susceptibles de r\u00e9pondre \u00e0 l\u2019ibrutinib (Imbruvica) que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire &nbsp;diff\u00e9rente de la maladie.<\/p>\n<p>Le lymphome diffus \u00e0 grandes cellules-B (DLBCL), forme agressive et rapidement envahissante de&nbsp; la maladie, est le plus courant du type non-Hodgkinien (LNH).<\/p>\n<p>Cette \u00e9tude men\u00e9e par le National Cancer Institute (NCI) en collaboration avec Pharmacyclics, de Sunnyvale, en Californie a d\u00e9montr\u00e9 que les&nbsp; patients avec le sous-type de DLBCL, \u00e0 cellules-B activ\u00e9es (lymphocytes B matures) (ABC) \u00e9taient plus susceptibles de r\u00e9agir \u00e0 l\u2019ibrutinib que les patients avec &nbsp;le sous-type de DLCBL \u00e0 cellules-B \u00e0 centre germinal (GCB), dans la phase II de l\u2019\u00e9tude.<\/p>\n<p>R\u00e9f\u00e9rences:&nbsp;&nbsp;<\/p>\n<p><a href=\"http:\/\/www.sciencedaily.com\/releases\/2015\/07\/150720114737.htm\">NIH\/National Cancer Institute. \u00ab\u00a0Study shows promise of precision medicine for most common type of lymphoma.\u00a0\u00bb ScienceDaily. ScienceDaily, 20 July 2015.<\/a><\/p>\n<p><a href=\"http:\/\/www.nature.com\/nm\/journal\/vaop\/ncurrent\/full\/nm.3884.html\">Targeting B-Cell Receptor Signaling with Ibrutinib in Diffuse Large B-Cell Lymphoma.&nbsp;<em>Nature Medicine<\/em>, July 2015<\/a><\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Une recherche r\u00e9cente a montr\u00e9 que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B (DLBCL) sont plus susceptibles de r\u00e9pondre \u00e0 l\u2019ibrutinib (Imbruvica) que des&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10,17],"tags":[],"class_list":{"0":"post-2396","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nouvelles","8":"category-recherche"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"Une recherche r\u00e9cente a montr\u00e9 que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B (DLBCL) sont plus susceptibles de r\u00e9pondre \u00e0 l\u2019ibrutinib (Imbruvica) que des...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-31T18:54:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\"},\"headline\":\"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib\",\"datePublished\":\"2015-07-31T18:54:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"articleSection\":[\"Nouvelles\",\"Recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\",\"name\":\"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"datePublished\":\"2015-07-31T18:54:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg\",\"width\":700,\"height\":300,\"caption\":\"masthead_ph_shadows\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/","og_locale":"fr_FR","og_type":"article","og_title":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada","og_description":"Une recherche r\u00e9cente a montr\u00e9 que des patients avec une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B (DLBCL) sont plus susceptibles de r\u00e9pondre \u00e0 l\u2019ibrutinib (Imbruvica) que des...","og_url":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_published_time":"2015-07-31T18:54:43+00:00","og_image":[{"width":700,"height":300,"url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@lymphomacanada","twitter_site":"@lymphomacanada","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#article","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/"},"author":{"name":"admin","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4"},"headline":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib","datePublished":"2015-07-31T18:54:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","articleSection":["Nouvelles","Recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/","url":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/","name":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","datePublished":"2015-07-31T18:54:43+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#primaryimage","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2013\/04\/masthead_ph_shadows.jpg","width":700,"height":300,"caption":"masthead_ph_shadows"},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/fr\/une-sous-categorie-moleculaire-specifique-de-lymphome-diffus-a-grandes-cellules-b-repond-bien-au-medicament-ibrutinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Une sous-cat\u00e9gorie mol\u00e9culaire sp\u00e9cifique de lymphome diffus \u00e0 grandes cellules-B r\u00e9pond bien au m\u00e9dicament ibrutinib"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]},{"@type":"Person","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/3f654528f96ee33030061e70192633c4","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8f0e240f88d3162ad64d22cede41425?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.lymphoma.ca\/fr\/author\/erezz_oxmaxp0p\/"}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=2396"}],"version-history":[{"count":0,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/posts\/2396\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media\/1771"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=2396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=2396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=2396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}